Physician profile
Allen Wang
NPI 1326434986
$4,461.44
in general payments reported to CMS, 2019-2025
29 companies · $1,709 in 2025
The $1,709 reported for 2025 was more than what 88% of Podiatrist providers received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $112 · 2020: $110 · 2021: $194 · 2022: $530 · 2023: $707 · 2024: $1,098 · 2025: $1,709.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,515.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,515.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $1,113.10 | 2022-2025 | Easyfuse, Actishield, Ortholoc 3di |
| Organogenesis INC. | $926.65 | 2023-2025 | Puraply Wound Matrix, Puraply, Via Matrix |
| Kerecis Limited | $326.24 | 2020-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Horizon Therapeutics Plc | $292.56 | 2019-2023 | Krystexxa |
| Smith+Nephew, INC. | $247.23 | 2020-2025 | Grafix, Collagenase Santyl, Grafix Pl |
| Treace Medical Concepts, INC. | $152.74 | 2022-2025 | |
| Convatec INC. | $127.79 | 2023-2025 | |
| Depuy Synthes Sales INC. | $124.26 | 2022-2025 | Na |
| Abbvie INC. | $121.84 | 2024 | |
| Paragon 28, INC. | $117.31 | 2023-2024 | Phantom Metatarsal Shortening, Phantom Intramedullary Nail, Mtp |
| Mimedx Group, INC. | $107.72 | 2024-2025 | |
| Osteomed LLC | $102.59 | 2021-2022 | |
| Zak Ortho | $102.27 | 2025 | |
| Medtronic, INC. | $69.13 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $62.01 | 2022-2023 | Seglentis |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioventus LLC | $59.00 | 2020-2022 | |
| Paratek Pharmaceuticals, INC. | $56.39 | 2024-2025 | Nuzyra |
| Nevro Corp. | $54.50 | 2022-2024 | Senza |
| Abbott Laboratories | $48.03 | 2023-2025 | Proclaim |
| Amgen INC. | $44.06 | 2025 | Krystexxa |
| Surgenex LLC | $40.92 | 2025 | Ardeograft, Renograft, Pellograft |
| Medwest Associates | $38.50 | 2023 | |
| Anika Therapeutics, INC. | $26.63 | 2021 | |
| Cashflow Solutions, LLC | $26.54 | 2025 | Lympha Press Optimal Plus(US) Bt, Pcd-51 731a (US) - White, Pcd-52 737a (US) White |
| Solventum Corporation | $15.40 | 2024 | Activ.A.C. |
| Reprise Biomedical, INC. | $15.37 | 2025 | Miro3d |
| Checkpoint Surgical, INC | $15.03 | 2021 | |
| Ibsa Pharma INC. | $13.89 | 2023 | Tirosint, Licart |
| Integra Lifesciences Corporation | $13.74 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allen Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.